The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

(2012) A Ruyssen-Witrand et al.   ANNALS OF THE RHEUMATIC DISEASES

Response to Rituximab and Timeframe to Relapse in Rheumatoid Arthritis Patients

(2012) Athina Pyrpasopoulou et al.   Molecular Diagnosis & Therapy

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

(2011) K. Chatzidionysiou et al.   ANNALS OF THE RHEUMATIC DISEASES

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study

(2011) Jérémie Sellam et al.   ARTHRITIS AND RHEUMATISM

Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3

(2011) T. Aung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

(2011) P. Emery et al.   RHEUMATOLOGY

The need for personalised medicine for rheumatoid arthritis

(2010) J. D. Isaacs et al.   ANNALS OF THE RHEUMATIC DISEASES

The CC homozygosis of the −174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis

(2010) Martina Fabris et al.   AUTOIMMUNITY REVIEWS

B cells in the pathogenesis and treatment of rheumatoid arthritis

(2010) Bethany Marston et al.   CURRENT OPINION IN RHEUMATOLOGY

Long-Term Effects of Rituximab in Rheumatoid Arthritis

(2009) Luca Quartuccio et al.   Annals of the New York Academy of Sciences

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

(2009) L. Quartuccio et al.   RHEUMATOLOGY

Contribution of Fc  receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis

(2008) M M Thabet et al.   ANNALS OF THE RHEUMATIC DISEASES

Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies

(2008) Julien Lejeune et al.   JOURNAL OF CLINICAL ONCOLOGY